Evidence map›Paper›PMID 40805202›Full record

ArticleCancers2025

Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced Pancreatic Cancer.

Ingvild Farnes, Caroline S Verbeke, Dyre Kleive, Anne Waage, Tore Tholfsen, Milada Hagen, Bjarte Fosby, Pål-Dag Line, Knut Jørgen Labori

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ingvild FarnesDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.ORCID 0009-0002-7738-7787
Caroline S VerbekeInstitute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.ORCID 0000-0002-1111-9715
Dyre KleiveDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.
Anne WaageDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.
Tore TholfsenDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.ORCID 0009-0004-6086-3585
Milada HagenDepartment of Health Science and Biostatistics, Oslo Metropolitan University, 0130 Oslo, Norway.
Bjarte FosbyDepartment of Transplantation Medicine, Oslo University Hospital, 0372 Oslo, Norway.
Pål-Dag LineInstitute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.ORCID 0000-0002-5884-9336
Knut Jørgen LaboriDepartment of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.ORCID 0000-0001-6777-7955

Funding

Norwegian Cancer Society 198039-2018 and 212734-2019South-Eastern Norway Regional Health Authority 2018088 and 2019029
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

borderline resectablehistopathologylocally advancedneoadjuvant therapyoverall survivalpancreatic cancerquality of lifesurgical complications

Identifiers

PMID40805202
PMCPMC12346083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.